---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009178"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:24:37.467979+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Orgenesis raises $2.3M in private placement of common stock and warrants

## Summary
- Sold 2,272,719 shares at $1.03 per share plus warrants for up to 2,272,719 shares at $1.50 and $2.00.
- Gross proceeds of ~$2.3M before expenses; proceeds for general corporate purposes.
- Offering closed March 5, 2024; warrants exercisable immediately, expire in 5 years.
- Participation includes healthcare industry executives and physicians.
- Securities sold under Regulation D exemption; not registered under Securities Act.

## SEC filing metadata
- accession: 0001493152-24-009178
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315224009178/0001493152-24-009178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315224009178/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009178
- JSON: https://secwatch.observer/filing/0001493152-24-009178.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009178.txt

## Key facts
- Material Agreements
  Orgenesis Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.3 million (effective 2024-03-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $2.3 million
  - Effective: 2024-03-03
  source text: On March 3, 2024, Orgenesis Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”), 2,272,719 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.03 per share (the “Shares”) and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $2.00 per share (collectively, the “Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315224009178/0001493152-24-009178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.